TB-500 Research for Corneal Healing
An evidence-based overview of research examining TB-500 in the context of corneal healing. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymosin beta-4's most advanced clinical application is in ophthalmology. The SEER-1 Phase 3 trial demonstrated that 60% of patients with neurotrophic keratopathy achieved complete corneal healing with RGN-259 (Tb4 eye drops) versus 31.9% with placebo. The mechanism involves promotion of corneal epithelial cell migration and reduction of inflammation via NF-kB suppression. Dry eye trials also showed improvements in corneal staining and tear breakup time. Note: These trials used RGN-259 (purified thymosin beta-4), not TB-500. The SEER-3 EU trial failed to meet its primary endpoint in 2025 due to stronger-than-expected placebo response.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Corneal Healing
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. TB-500 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.